Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver disease
Biotech
D&D sees fibrosis improvements, MASH resolution on GLP-1 drug
D&D linked its GLP-1/glucagon drug to liver health improvements, keeping the Korean biotech in the hunt for a market already served by Novo's Wegovy.
Nick Paul Taylor
May 27, 2026 10:30am
Ipsen scuttles liver disease candidates from Albireo acquisition
May 6, 2026 3:10pm
Madrigal boosts MASH pipeline with $1B biobucks Arrowhead deal
May 5, 2026 10:40am
Mirum maps FDA path after anti-itch candidate scores ph. 2 win
May 4, 2026 10:40am
BioVie plans $20M IPO for spinout developing liver disease drug
Mar 17, 2026 5:18am
Alfasigma's $690M deal for GSK itch drug awaiting FDA decision
Mar 9, 2026 6:55am
